CommentaryPublished 30 Jun 2022
A Short Note on Current and Novel Inhibitors of HIV Protease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The design, development and clinical success of HIV peptidase inhibitors represent one among the foremost outstanding achievements of molecular drugs. This review describes all 9 presently out there FDA-approved peptidase inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds within the varied stages of clinical development are introduced, as well as alternative approaches, aiming at different purposeful domains of HIV PR. The potential of these novel compounds to open new thanks to the rational drug style of human viruses is critically assessed.
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biochemistry Research
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Romica Cretu”